DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Branch Retinal Vein Occlusion

Intervention: Bevacizumab (Drug); Triamcinolone Acetonide (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Shahid Beheshti Medical University


This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Clinical Details

Official title: Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Visual acuity

Secondary outcome: central macular thickness


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Recent onset (less than 3 months) BRVO

Exclusion Criteria:

- Any previous intervention

Locations and Contacts

Imam Hossein medical center, Tehran, Iran, Islamic Republic of; Recruiting
Alireza Ramezani, Assistant professor, Email: arramezani@gmail.com
Alireza Ramezani, Assistant professor, Principal Investigator
Additional Information

Starting date: January 2010
Last updated: January 6, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017